Bioxcel Therapeutics Logo

Board of Directors

Peter Mueller, Ph.D.

Chairman of the Board

Dr. Peter Mueller is currently the President of the Mueller Health Foundation, a private foundation…

LEARN MORE

June Bray

Board Member

Ms. Bray brings over 40 years of extensive U.S. and global regulatory experience in the healthcare industry…

LEARN MORE

Sandeep “Steve” Laumas, M.D.

Board Member

Dr. Laumas currently serves as the Chief Business Officer and Chief Financial Officer of Instil Bio, Inc. …

LEARN MORE
David Mack

David Mack

Board Member

Mr. Mack is a senior fiduciary and restructuring and credit lawyer with nearly 30 years of finance, mergers and acquisitions…

LEARN MORE

Vimal Mehta, Ph.D.

Chief Executive Officer & Founder

Dr. Vimal Mehta is the Co-Founder, Chief Executive Officer, and a member of the Board of Directors…

LEARN MORE

Michael P. Miller

Board Member

Mr. Miller brings nearly 40 years of strategic leadership and commercial growth experience in the pharmaceutical industry…
LEARN MORE
Rajiv Patni

Rajiv Patni, M.D.

Board Member

Dr. Rajiv Patni is a biopharmaceutical industry veteran with extensive experience in global product development…

LEARN MORE

Michal Votruba

Board Member

Mr. Votruba has been the Director of the Gradus/RSJ Life Sciences Fund, the largest dedicated fund in Central Europe with a portfolio…

LEARN MORE
Bioxcel Therapeutics Logo
Linkedin-in Twitter

IGALMI is a registered trademark of BioXcel Therapeutics, Inc. 
All other trademarks are the properties of their respective owners.
Copyright © 2025 BioXcel Therapeutics Inc. All Rights Reserved. US-IGA-2300177

IGALMI is a registered trademark of BioXcel Therapeutics, Inc.
All other trademarks are the properties of their respective owners.
Copyright © 2025 BioXcel Therapeutics Inc. All Rights Reserved. US-IGA-2300177

Scroll to Top
Peter Mueller

Peter Mueller, Ph.D.

Chairman of the Board

Dr. Peter Mueller is President of the Mueller Health Foundation, a private foundation tackling globally lethal infectious diseases such as tuberculosis by addressing latency and the ever-growing challenges of antimicrobial resistance. From 2014 to 2016, Dr. Mueller was President of R&D and Chief Scientific Officer at Axcella Health. Prior to joining Axcella, Dr. Mueller served as Executive Vice President of Global Research and Development & Chief Scientific Officer at Vertex Pharmaceuticals where he provided strategic oversight for Vertex’s worldwide drug discovery and development programs. Under his leadership, the company secured approval for and launched two breakthrough drugs, INCIVEK® (HepC) in 2011, and KALYDECO® (CF) in 2012. Additionally, Vertex submitted both an NDA and MAA for ORKAMBI® (CF). 

Prior to his time at Vertex, Dr. Mueller served as Senior Vice President, Research and Development, for Boehringer Ingelheim Pharmaceuticals, Inc., where he played a key role in the development of Spiriva®, Combivent®, and Atrovent®. He is a member of various scientific and political societies, including the Gesellschaft Deutscher Chemiker (GDCh) and Verband Chemische Industrie (Germany), Royal Society of Chemistry (U.K.), IRI, RNA-Society, ASAP, AAAS (U.S.A.) and currently serves on the Boards of Directors and Scientific Advisory Boards of companies and organizations including US-India Chamber of Commerce Biotech, Pharma & Medical Devices Council, University Iowa (CBB), Keystone Symposia, Inhibikase Therapeutics, Inc., and Kaleido Biosciences, Inc. 

Dr. Mueller received both an undergraduate degree and a Ph.D. in chemistry at the Albert Einstein University of Ulm, Germany, where he also holds a Professorship in Theoretical Organic Chemistry. He completed fellowships in Quantum Pharmacology at Oxford University and in Biophysics at Rochester University.

June Bray

Board Member

Ms. Bray brings over 40 years of extensive U.S. and global regulatory experience in the healthcare industry. She most recently served as Senior Vice President, Global Regulatory Affairs and Medical Writing at Allergan, where she was responsible for regulatory strategies on development projects and lifecycle management in all therapeutic areas, including psychiatry and neurology. During her tenure, she led numerous NDA approvals, including Namenda XR®, Namzaric®, Vraylar®, and Ubrelvy®. Previously, Ms. Bray served as Vice President, Regulatory Affairs at Organon (now Merck), where she led regulatory activities for development and marketed products, including the NDA for Saprhis® (asenapine) for the treatment of schizophrenia and bipolar disorder. 

Earlier in her career, Ms. Bray held numerous roles of increasing responsibility over a 25-year period at Berlex Laboratories, Inc. (now Bayer HealthCare Pharmaceuticals). She began her pharmaceutical career in sterile manufacturing at Hoechst-Roussel Pharmaceuticals (now Sanofi-Aventis). Ms. Bray holds a B.S. in Pharmacy from the University of Rhode Island and an M.B.A in Pharmaceutical Marketing from Fairleigh Dickinson University.

Sandeep Laumas

Sandeep “Steve” Laumas, M.D.

Board Member

Dr. Laumas currently serves as the Chief Business Officer and Chief Financial Officer of Instil Bio, Inc. Prior to joining Instil Bio, Dr. Laumas has been actively involved in healthcare investing and serving on company Boards of Directors. He currently serves as a member of the board of directors of BioXcel Therapeutics, Inc. and 9 Meters Biopharma, Inc. He began his career at Goldman Sachs & Co. in New York in the Investment Banking Division. Dr. Laumas then joined Balyasny Asset Management in New York and later moved to North Sound Capital as a Managing Director responsible for global healthcare investments. He has been investing in healthcare via investment vehicles, Bearing Circle Capital. Dr. Laumas has served as a director of Parkway Holdings Ltd. (IHH Healthcare) and SRL Ltd. He has a unique industry perspective, particularly in both public and private investments and financial transactions in the healthcare arena. 

Dr. Laumas received his A.B. in Chemistry from Cornell University in 1990, his M.D. from Albany Medical College, with a research year at the Dana-Farber Cancer Institute, and completed his medical internship at Yale University School of Medicine.

David Mack

David Mack

Independent Director

Mr. Mack is a senior fiduciary and restructuring and credit lawyer with nearly 30 years of finance, mergers and acquisitions, and restructuring experience in complex domestic and international litigation, leading transactions as a director, investor, and advisor. He has worked for top-tier law and investment firms in the United States, United Kingdom, and Australia. His areas of expertise include corporate governance, litigation, capital markets, and corporate law.

Mr. Mack is currently a fiduciary at Drivetrain LLC in New York City. Previously, he worked as an Independent Director at Terraform Global, Inc., as Managing Director at Perry Capital, LLC., and as Bankruptcy/Credit Practice Counsel at Simpson Thacher & Bartlett LLP. Earlier in his career, he worked as Solicitor at Linklaters in London, UK; and at Mallesons Stephen Jaques in Sydney, Australia.

Mr. Mack is a member of the New York Bar and is admitted to practice law in the United Kingdom and Australia. He received a B.A. in Government and Economic History and an LLB from the University of Sydney.

Vimal Photo

Vimal Mehta, Ph.D.

Chief Executive Officer & Founder

Dr. Vimal Mehta is the Co-Founder, Chief Executive Officer, and a member of the Board of Directors of BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence (AI) approaches to develop transformative medicines in neuroscience and immuno-oncology. He has more than 25 years of leadership in the pharmaceutical and biotech industries. Dr. Mehta successfully built and led innovative drug discovery and development companies that have helped bring novel therapies to market to address major unmet medical needs and positively impact the lives of patients, caregivers, and clinicians.

In 2006, Dr. Mehta co-founded BioXcel LLC, which pioneered the application of big data analytics and machine learning-based AI integrated with drug-development expertise. In 2017, he co-founded BioXcel Therapeutics as a spinout and led the company’s Initial Public Offering in 2018. He has now raised approximately $500 million in capital to support the company’s R&D and commercial efforts. Through his leadership, BioXcel Therapeutics has built a unique AI-based drug discovery and development capability and advanced from first-in-human clinical trials to FDA approval of IGALMI™ and commercial launch in under four years. Developed as BXCL501, IGALMI™ is a proprietary, sublingual film formulation of dexmedetomidine approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

In 2022, Dr. Mehta led strategic financing agreements of $260 million with Oaktree Capital Management, L.P. and Qatar Investment Authority to support the company’s commercial activities for IGALMI, expand clinical development of BXCL501 — including a pivotal Phase 3 program for acute agitation in patients with Alzheimer’s disease as well as the at-home use of BXCL501 for acute agitation in bipolar and schizophrenia patients — and advance additional neuroscience and immuno-oncology clinical programs. He also led the formation of OnkosXcel Therapeutics as a subsidiary of BioXcel Therapeutics to develop transformative medicines in oncology.

Dr. Mehta has been recognized for healthcare leadership, including New Haven Biz naming him in its “Power 25 Healthcare 2022” list of leaders for “making strides developing treatments for cancer and agitation in people suffering from Alzheimer’s disease, schizophrenia, and bipolar disorder.” Also in 2022, the Healthcare Technology Report ranked Dr. Mehta among the top 25 healthcare technology leaders in Connecticut. In addition, BioXcel Therapeutics was named Therapeutics Company of the Year for 2022 in the annual BioTech Breakthrough Awards, while the Hartford Business Journal recognized the company among area “healthcare heroes.”

In addition to his roles at BioXcel Therapeutics, Dr. Mehta is Chairman of the Board and CEO of BioXcel LLC and serves on the Board of several other companies. Earlier in his career, he worked for several leading pharmaceutical companies in senior-level business-development capacities. He was also Assistant Professor at UT Southwestern Medical Center in Dallas, USA. 

Dr. Mehta holds a Ph.D. in chemistry from the University of Delhi, India and completed a Post-Doctoral Fellowship in chemistry at the University of Montpellier, France.

Michael P. Miller

Michael P. Miller

Board Member

Mr. Miller brings nearly 40 years of strategic leadership and commercial growth experience in the pharmaceutical industry, where he most recently served as Executive Vice President, U.S. Commercial at Jazz Pharmaceuticals. In this role, Mr. Miller led a 450+ person team that generated $2.3 billion in revenues in 2020 and led all commercial operations for drugs including Xyrem® and Sunosi® for neurological disorders and Vxyeos®, Erwinaze®, Defitelio®, and Zepzelca® for difficult-to-treat cancers. Prior to Jazz, he served in senior executive management positions with commercial, marketing, market access, and sales responsibilities at VIVUS, Genentech (until acquisition by Roche), Connetics Corporation, and ALZA Corporation. He began his pharmaceutical career at Syntex Laboratories until its acquisition by Roche. 

Mr. Miller currently sits on the Board of Puma Biotechnology and serves as an advisor to several private and public clinical-stage biotechnology companies. He previously sat on the Board of the Leukemia and Lymphoma Society, Silicon Valley and Monterey Chapter. Mr. Miller holds a B.S. in Finance from the University of San Francisco and an MBA from San Francisco State University.

Rajiv Patni

Rajiv Patni, M.D.

Board Member

Dr. Rajiv Patni is a biopharmaceutical industry veteran with extensive experience in global product development in a diverse set of therapeutic areas, including cardiology, diabetology, hepatology, neurology, and benign hematology. Since September 2024, Dr. Patni has served as the Chief Executive Officer of Judo Bio, a biopharmaceutical development company focused on pioneering oligonucleotide medicines delivered to the kidney. He previously served as Chief Research and Development Officer at Reata Pharmaceuticals, a commercial-stage company acquired by Biogen, and is currently serving as a board member of Quince Therapeutics, Inc. (Nasdaq: QNCX). Previously, Dr. Patni also served as Chief Medical Officer at several public, commercial-stage biopharmaceutical companies – Global Blood Therapeutics, Portola Pharmaceuticals, and Adamas Pharmaceuticals, until their acquisitions by larger companies. Earlier in his career, Dr. Patni held roles of increasing responsibility at Pfizer, Roche, and Actelion.

Dr. Patni received his M.D. from the Icahn School of Medicine at Mount Sinai in New York City as part of an accelerated B.S./M.D. program. He completed an internal medicine residency and adult cardiology fellowship at the Albert Einstein College of Medicine, also in New York City, where he continued as an attending physician-scientist before joining the biopharmaceutical industry.

Michal Votruba

Michal Votruba

Board Member

Since 2013, Mr. Votruba has been Director of the Gradus/RSJ Life Sciences Fund, the largest dedicated fund in Central Europe with a portfolio of companies in Europe and the United States. Mr. Votruba has served as a director of Mynd Analytics, Inc. (NASDAQ: MYND), a telebehavioral health services company, since July 2015. Since 2010, he has served as a member of the board of PrimeCell Therapeutics as the Director of Global Business Development overseeing the expansion of the largest regenerative medicine company operating in Central Europe. In 2009, the Czech Academy of Sciences solicited Mr. Votruba’s expertise for the first successful privatization project of the Institute of Experimental Medicine in Prague: the newly created protocol established a precedent for future privatization projects in the Czech Republic. 

Mr. Votruba graduated as a Clinical Psychiatrist from the Medical Faculty of Charles University in Prague in 1989. Shortly thereafter, he emigrated from Czechoslovakia and developed his professional career in Canada and the United States. Since 2005, Mr. Votruba combined his theoretical and clinical experience in the field of Competitive Intelligence, serving the global pharmaceutical industry for eight years as an industry analyst advising senior leaders of companies including Amgen, Novartis, Eli Lilly, Allergan, EMD, Serono, and Sanofi.

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries. This web site is intended to help healthcare professionals practicing in the US find scientifically balanced, evidence-based information about Bioxcel Therapeutics drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.